| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
MT1 8.9 (pKi) MT2 9.1 (pKi)
MT1 and MT2 melatonin receptors. 6-Chloromelatonin is a high-affinity agonist at these receptors. |
|---|---|
| ln Vitro |
6-Chloromelatonin competes with human platelets (Ki=11.4 nM) for [3H]-melatonin binding sites[3]. Human chorionic gonadotrophin (hCG-beta) baseline levels were unaffected by 6-chloromelatonin (10 pM, 1 nM, 100 nM, 10 μM; 72 hours), but it inhibits forskolin-stimulated hCG-beta production in JEG-3 and BeWo cells in a dose-dependent manner[4].
6-Chloromelatonin is a potent melatonin receptor agonist with greater metabolic stability than melatonin. It competes for [3H]-melatonin and 2-[125I]-iodomelatonin binding to MT1 receptors with pKi values of 8.9 and 9.1, respectively. The compound shows higher affinity for binding to hamster brain membrane and chicken retina than melatonin. It has antiproliferative activity and is active at nanomolar concentrations. |
| ln Vivo |
Rats given a 0.5 mg/kg injection of the melatonin agonist 6-chloromelatonin the day following the phase shift excreted significantly more 6-sulphatoxymelatonin than did the controls[5].
No detailed in vivo activity data are publicly available for 6-Chloromelatonin. As a potent melatonin receptor agonist with improved metabolic stability, its in vivo effects would be expected to be related to the physiological roles of melatonin, including regulation of circadian rhythms, sleep, and neuroprotection. |
| Enzyme Assay |
In vitro receptor binding assays are performed to determine the affinity of 6-Chloromelatonin for MT1 and MT2 receptors. Radioligand binding studies using membrane preparations from cells or tissues expressing the receptors are conducted. The compound's ability to displace [3H]-melatonin or 2-[125I]-iodomelatonin from the receptors is measured to calculate its pKi values.
|
| Cell Assay |
In vitro cell-based assays are conducted using cells expressing recombinant MT1 or MT2 receptors. The cells are treated with 6-Chloromelatonin, and receptor activation is measured by assessing downstream signaling events such as inhibition of cAMP accumulation. The potency of the compound at each receptor is determined from these functional assays.
|
| Animal Protocol |
In vivo studies would be conducted in animal models to evaluate the effects of 6-Chloromelatonin on circadian rhythms, sleep, and other melatonin-mediated processes. The compound's improved metabolic stability compared to melatonin may result in a longer duration of action in vivo.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data are publicly available for 6-Chloromelatonin. The compound's greater metabolic stability compared to melatonin suggests that it may have a longer half-life and improved bioavailability. Its ADME properties would be characterized in standard preclinical studies.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are publicly available for 6-Chloromelatonin. As a melatonin receptor agonist, its toxicity profile is expected to be related to its mechanism of action. Standard safety assessments would be required for any therapeutic development.
|
| References | |
| Additional Infomation |
N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)ethyl]acetamide is a member of the acetamide class of compounds.
6-Chloromelatonin is a synthetic indoleamine and a high-affinity agonist for melatonin receptors MT1 and MT2. It is a potent melatonin receptor agonist with greater metabolic stability than melatonin. The compound shows higher affinity for binding to hamster brain membrane and chicken retina than melatonin and has antiproliferative activity. It is not approved for human therapeutic use and is strictly for research purposes. |
| Molecular Formula |
C13H15CLN2O2
|
|---|---|
| Molecular Weight |
266.72
|
| Exact Mass |
266.082
|
| CAS # |
63762-74-3
|
| PubChem CID |
1858
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.272g/cm3
|
| Boiling Point |
536.7ºC at 760 mmHg
|
| Flash Point |
278.4ºC
|
| Index of Refraction |
1.608
|
| LogP |
2.899
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
301
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C=C2C(C(CCNC(=O)C)=CN2)=CC=1OC
|
| InChi Key |
LUINDDOUWHRIPW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H15ClN2O2/c1-8(17)15-4-3-9-7-16-12-6-11(14)13(18-2)5-10(9)12/h5-7,16H,3-4H2,1-2H3,(H,15,17)
|
| Chemical Name |
N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)ethyl]acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7493 mL | 18.7463 mL | 37.4925 mL | |
| 5 mM | 0.7499 mL | 3.7493 mL | 7.4985 mL | |
| 10 mM | 0.3749 mL | 1.8746 mL | 3.7493 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
